Wagner Farid Gattaz

• Abstract

  As in other areas of knowledge, there has been an intense degree of informatization of the scientific activities applied to Psychiatry, Psychology and Neurosciences, in parallel to the rapid growth of clinical and neurobiological databases of research. As expected, this growing wave of informatization has been brought to the Institute of Psychiatry (IPq), one of the six Institutes of Clin…

  Remake and extention of computational infrastructure for research groups at IPq-HCFMUSP, AP.RT.INST

• Abstract

  The search for the biological substrate of neuropsychiatric diseases is a pre-requisite for the development of more efficient therapies and, most importantly, preventive strategies by means of early diagnosis. The experimental attempts to identify specific markers for the different diseases remain unsuccessful. At least partially, these negative results derive from a probable lack of spec…

  National Institute for Biomarkers in Neuropsychiatry, AP.EMU

• Abstract

  The search for the biological substrate of neuropsychiatric diseases is a pre-requisite for the development of more efficient therapies and, most importantly, preventive strategies by means of early diagnosis. The experimental attempts to identify specific markers for the different diseases remain unsuccessful. At least partially, these negative results derive from a probable lack of spec…

  National Institute for Biomarkers in Neuropsychiatry, AP.EMU

(Only some records are available in English at this moment)

• Abstract

  In view of the socio-demographic challenges imposed and the high functional impact of Alzheimer's disease (AD), it is important to carry out studies that aim to uncover the pathophysiological mechanisms underlying this disease. Such understanding will broaden the spectrum of substrates with potential use as biomarkers, thus contributing to early diagnoses, as well to discover pathological…

  Peripheral determination of iPLA2 enzyme activity and evaluation of functional markers of the blood-brain barrier in patients with Alzheimer's Disease, BP.IC

• Abstract

  Schizophrenia is a psychiatric disease that affects around 1% of the world's population, and comprises a number of heterogeneous symptoms complicating treatment. Above all, several environmental and genetic factors influence its etiology and, therefore, diagnosing the disease before it manifests itself is a further step towards treatment, characterizing this group in UHR (ultra high risk)…

  Alterations in the inflammatory pathway of Cox: risk for the development of schizophrenia, BP.MS

• Abstract

  Psychotic disorders are frequent conditions that affect around 3.5% of the general population. Schizophrenia (SCZ) - the most frequent psychotic disorder - affects about 1% of the population, tends to be chronic and disabling. Even before presenting psychosis sympthoms, patients present behavioral changes that allow to follow and track these individuals. Based on some clinical and demogra…

  Peripheral markers of membrane metabolism: characterization of individuals at ultra-high risk for psychosis, BP.DR

(Only some records are available in English at this moment)

• Abstract

  Schizophrenia is a complex psychiatric disorder that affects about 1% of the world's population. Despite considerable progress in recent years, the etiology of the disease has not yet been clarified. The beginning and the progression of the disease are heterogeneous and often the patients' symptoms are common to other neuropsychiatric disorders, making differentiation and diagnosis throug…

  Proteomics of schizophrenia: the search for biomarkers in platelets, BE.EP.DR